IVF | Jotup

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on:

水曜日, 3月 20, 2024

Infertility, TMSC, Pregnancy rate, IVF, IUI, Pregnancy, Fertilisation, Woman, Male, Safety, Literature, FDA, ICSI, Insemination, Physician, Birth control

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points:

The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
“These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
“The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

Retrieved on:

水曜日, 3月 13, 2024

ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

ATLANTA, March 13, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces it will participate in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.

Key Points:

Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.
will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

China In-Vitro Fertilization Market Research Report 2023-2030 Featuring Vitrolife, Cloudnine, Nova IVI Fertility, Monash, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono - ResearchAndMarkets.com

Retrieved on:

金曜日, 3月 22, 2024

General Health, Other Health, Consumer, Health, Baby, Maternity, Consciousness, Infertility, Prevalence, IVF, Sterilization, Fertility, Fertilisation, Woman, Male, Infection, Patient safety, ICSI, Birth control

Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.

Key Points:

Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.
Disposable devices are predicted to be among the instruments used considerably in the China In-Vitro Fertilization (IVF) market.
ICSI IVF is foreseen to be among the considerably utilized processes in the China In-Vitro Fertilization (IVF) market.
Fertility clinics are projected to experience a considerable increase in utilization in the China In-Vitro Fertilization (IVF) market.

Reproductive Medicine Associates Opens New State-of-the-Art Fertility Center and IVF Lab in Bellevue, Expanding Access to Fertility Care in Washington State

Retrieved on:

水曜日, 3月 13, 2024

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.

Key Points:

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.
The clinic is RMA’s second location in Washington state, after Seattle, and adds to an extensive network of more than sixty RMA clinics across the United States.
“We’re committed to expanding access to cutting-edge fertility care for the roughly 1 in 5 Americans who struggle with infertility,” said Lynn Mason, CEO of IVI RMA America.
The center will also offer family planning resources and options for LGBTQ+ individuals and fertility preservation treatments for those individuals with autoimmune diseases or cancer diagnoses.

ResumeBuilder.com Survey Reveals 3 in 10 Workers Are Unlikely To Consider Jobs in States With IVF Restrictions

Retrieved on:

木曜日, 4月 4, 2024

Fertilisation, Private practice, Employment, IVF, Ageing, Work, Legislation, Woman

SEATTLE, April 4, 2024 /PRNewswire-PRWeb/ -- ResumeBuilder.com, the premier resource for professional resume templates and career advice, has published a recent survey report investigating the impact of reproductive care public policies on workers' employment location preferences. The report also provides valuable insights into workers' attitudes toward legislation prohibiting in vitro fertilization. The survey collected responses from 1,250 employed adults in the United States.

Key Points:

The survey collected responses from 1,250 employed adults in the United States.
"Public policies affecting women's health care are impacting where Americans want to live and work," says Stacie Haller.
Within this group, 51 percent say there is nothing that would make them more likely to consider a job offer in one of these states.
Among respondents, 30 percent report they are unlikely to consider a job offer in a state that has passed legislation effectively banning IVF.

Gameto Announces Patient Experience Data Demonstrating Investigational In Vitro Maturation Solution Well Tolerated with Higher Patient Satisfaction Rates than Conventional Fertility Stimulation

Retrieved on:

火曜日, 4月 2, 2024

NEW YORK, April 2, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation (COS) in combination with Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, affected patients' egg retrieval experiences when compared to conventional stimulation. The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).

Key Points:

The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).
"We are encouraged by these and previously published efficacy data which demonstrate that combining minimal hormonal stimulation with our investigational in vitro maturation solution may help women navigating fertility treatments avoid many of the common side effects associated with the conventional IVF hormone protocol.
Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population.
[1],[2] In contrast, the participants in this analysis who underwent minimal ovarian stimulation cycles followed by OSC-IVM yielded no incidence of OHSS.

TMRW Life Sciences Launches CryoLink for Fertility Clinics to Quickly & Easily Upgrade to a Safe Digital Management System for Frozen Egg & Embryo Storage

Retrieved on:

火曜日, 3月 19, 2024

RFID, Risk, EMR, Patient, IVF, Internet, Fertility, SMS, Computer, HIPAA, Investment, Safety, FDA, TMRW, Warehouse

NEW YORK, March 19, 2024 /PRNewswire/ -- TMRW Life Sciences (TMRW), a fertility technology company setting a new standard of care in IVF labs, today announced the launch of CryoLink, a workstation that facilitates the digital management of fertility clinics' frozen specimen inventory. The introduction of CryoLink enables the use of TMRW's Digital Specimen Management system with or without TMRW's automated storage platforms.

Key Points:

The introduction of CryoLink enables the use of TMRW's Digital Specimen Management system with or without TMRW's automated storage platforms.
Until now, fertility clinics could only access TMRW's Digital Specimen Management system by adopting its automated storage platforms, which have both automated storage and digital specimen management.
CryoLink now enables TMRW's Digital Specimen Management system to be used with a wide range of storage options thereby enabling easier, faster adoption by clinics.
CryoLink can be used with TMRW's automated storage platforms, TMRW's offsite storage facilities and/or traditional storage tanks currently used by fertility clinics.

Stork Club Fertility Outcomes Exceed National Benchmarks With Independent Validation

Retrieved on:

月曜日, 3月 18, 2024

Milliman, Health, ROI, Conference, The Conference Board, SAN, IVF, Center of excellence, COE, Patient, Child, Stork Club, MD, Club, Booth, Spine, Storey, Reproductive endocrinology and infertility, Birth control

SAN FRANCISCO, March 18, 2024 /PRNewswire/ -- Stork Club, a pioneering enterprise reproductive care benefits solution, announced today that it outperforms national averages on all key performance measures. This leads to significantly fewer IVF cycles, and healthier pregnancies, births, and babies born via IVF compared with the US average. These results, validated by an independent auditor, come after Stork Club launched Performance Guarantees for 100% cost accountability tied to the clinical and financial outcomes provided to employers.Stork Club engaged Milliman, Inc., an independent global leader in actuarial services, to evaluate its approach for comparing its results against national benchmarks. In its evaluation, Milliman actuaries concluded that Stork Club's methodology is appropriate and reasonable for estimating clinical performance differences between the national population and individuals who received care under Stork Club's coverage across six key performance metrics.Stork Club's most recently published outcomes are the following:

Key Points:

These results, validated by an independent auditor, come after Stork Club launched Performance Guarantees for 100% cost accountability tied to the clinical and financial outcomes provided to employers.
Stork Club engaged Milliman, Inc. , an independent global leader in actuarial services, to evaluate its approach for comparing its results against national benchmarks.
Stork Club helps steer patients to fertility clinics that drive better outcomes while still giving patients the flexibility to select a provider of their choice.
Stork Club collects outcomes data directly from its providers via proprietary software to enable real-time proactive care management for its patients.

Hyundai Auto Canada recognized among 2024 Best Workplaces for Women

Retrieved on:

水曜日, 3月 13, 2024

Hyundai Canada's leadership pipeline initiates successfully retained and promoted female team members, with 50 per cent national managers self-identifying women.

Key Points:

Hyundai Canada's leadership pipeline initiates successfully retained and promoted female team members, with 50 per cent national managers self-identifying women.
MARKHAM, ON, March 13, 2024 /CNW/ - Hyundai Auto Canada (HAC) has been recognized on the 2024 Best Workplaces™ for Women list by Great Place to Work®.
Hyundai Canada on the list of Best Workplaces™ for Women in 2019, 2021,2022, and 2023.
The Organization was first certified as a Great Place to Work in 2017 and has appeared on the Canada's Best Workplaces® list every year starting in 2018.

Alife Health Partners with Boston IVF on AI Technology for IVF Treatment Optimization

Retrieved on:

火曜日, 3月 12, 2024

Algorithm, Infertility, Stim, Partnership, SAN, Patient, IVF, Research, AI, Machine learning, Reproductive medicine, Medical device

SAN FRANCISCO and BOSTON, March 12, 2024 /PRNewswire/ -- Alife Health ("Alife"), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF, a leading fertility clinic with more than 25 locations across the U.S., to pilot the country's first AI tool for IVF medication optimization. Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.

Key Points:

SAN FRANCISCO and BOSTON, March 12, 2024 /PRNewswire/ -- Alife Health ("Alife"), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF , a leading fertility clinic with more than 25 locations across the U.S., to pilot the country's first AI tool for IVF medication optimization.
Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.
The collaboration aims to advance the field of reproductive medicine by combining Alife's state-of-the-art AI technology with the expertise of Boston IVF's world-renowned fertility specialists.
"Our partnership with Alife marks a major milestone in the advancement of AI technology for fertility treatment," says David Stern, CEO of Boston IVF.